高级检索
当前位置: 首页 > 详情页

Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma

文献详情

资源类型:
Pubmed体系:
机构: [1]Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden [2]Guangdong Provincial Key Laboratory of Human Disease Genomic, Shenzhen Key Laboratory of Genomics, BGI Research, Shenzhen, China [3]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China [4]Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden [5]Department of Biomedical Engineering, Yale University, New Haven, CT, USA [6]Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden [7]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China [8]Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China [9]Kindstar Global Precision Medicine Institute, Wuhan, China [10]Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA [11]BGI Genomics, Shenzhen, China [12]Laboratory for Pediatric Immunology, Department of Pediatrics, Willem Alexander Children’s Hospital, Leiden University Medical Center, Leiden, the Netherlands
出处:

摘要:
Mantle cell lymphoma (MCL) is a rare but often aggressive type of B cell lymphoma with a high risk of relapse. To explore intratumoral clonal diversity and tumor evolution related to disease relapse, we integrate single-cell RNA and B cell receptor sequencing with whole-genome sequencing in 20 diagnosed/untreated and/or relapsed samples from 11 MCL patients. Our results reveal significant intratumor heterogeneity in MCL already at diagnosis. We further show that the evolutionary paths during disease progression for each patient are unique, where minor clones present at diagnosis may acquire different mutations and copy-number variations and/or migrate to various microenvironments. Despite significant interpatient heterogeneity, recurrent genetic and transcriptomic changes in tumor cells affecting key signaling pathways, along with alterations involved in the tumor microenvironment, are also observed during disease progression. Taken together, our findings elucidate the diverse and dynamic tumor-immune evolution processes associated with disease progression and relapse in MCL.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验 2 区 细胞生物学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 医学:研究与实验 2 区 细胞生物学
第一作者:
第一作者机构: [1]Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
共同第一作者:
通讯作者:
通讯机构: [2]Guangdong Provincial Key Laboratory of Human Disease Genomic, Shenzhen Key Laboratory of Genomics, BGI Research, Shenzhen, China [11]BGI Genomics, Shenzhen, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65768 今日访问量:2 总访问量:5150 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号